-

Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment

SEATTLE & VANCOUVER, British Columbia--(BUSINESS WIRE)--Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) and SōRSE Technology Corporation (“SōRSE”) have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the cannabinoid PAS-393 towards clinical testing against cancer.

“This progress is very promising because this step is critical for testing in human volunteers,” said Pascal CEO Patrick Gray. “We will next identify a drug product manufacturer to prepare our product for testing in cancer patients treated with checkpoint inhibitors.”

It will be the first pharmaceutical use of the novel formulation technology developed by SōRSE and the first clinical trial for Pascal and SōRSE. This collaboration utilizes propriety discoveries by both companies, including Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors, and SōRSE’s proprietary formulation expertise.

“It’s great to see such rapid progress with the in vitro studies using our formulation technology,” said SōRSE CEO Howard Lee. “We are on track to enter our first clinical trial with Pascal within a year.”

Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SōRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor.

About Pascal Biosciences Inc.

Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. For more information, visit www.pascalbiosciences.com.

About SōRSE Technology

SōRSE Technology Corporation is a water-soluble emulsion technology designed for product developers to provide consumers with a better, more consistent cannabinoid experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Its patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for infusing CBD and other functional ingredients into beverages, food items, topicals, and medical applications. SōRSE Technology currently powers more than 45 leading products in the CBD space. For more information, visit www.sorsetechnology.com.

Contacts

SōRSE Technology Press:
Jon Lindsay Phillips
RLM PR
SorseTech@rlmpr.com
+1-646-828-8566

SōRSE Technology Logo
SōRSE Technology Logo

SōRSE Technology

Details
Headquarters: Seattle, Washington
CEO: Howard Lee
Employees: 73
Organization: PRI

Release Versions

Contacts

SōRSE Technology Press:
Jon Lindsay Phillips
RLM PR
SorseTech@rlmpr.com
+1-646-828-8566

More News From SōRSE Technology

SōRSE Technology Enters Brewing Industry With New Product Offering Made in Partnership With Yakima Chief Hops

SEATTLE--(BUSINESS WIRE)--SōRSE Technology, the leading water-soluble emulsion provider for infused CPG brands, in partnership with Yakima Chief Hops, the leading 100% grower-owned hop supplier, announced today its newest product offering for brewers, Water-Soluble CBD Distillate. With more than six generations of commercial farming knowledge, the Yakima Chief Hemp growers cultivate their hemp with the same quality best practices and consistency as their hops, due in part to the similarities be...

SōRSE Technology Starts $4M Convertible Note Offering with $2M Lead Investment from Private Equity Cannabis Firm Merida Capital Holdings

SEATTLE--(BUSINESS WIRE)--SōRSE Technology Corporation (the “Company” or “SōRSE”), a leading water-soluble emulsion technology company, announces the completion of a $2M lead investment in its convertible note offering with private equity firm, Merida Capital Holdings. The investment will fund further innovation and scalability as SōRSE expands its offerings beyond cannabinoids. SōRSE anticipates completing the fundraising for this convertible note offering in May 2021. SōRSE has prioritized de...

SōRSE Technology Enters into Distribution Agreement with Medara S.A. to Increase Accessibility of Water-Soluble Cannabinoids in Latin America

SEATTLE & MONTEVIDEO, Uruguay--(BUSINESS WIRE)--SōRSE Technology Enters into Distribution Agreement with Medara S.A. to Increase Accessibility of Water-Soluble Cannabinoids in Latin America...
Back to Newsroom